CJC-1295 vs Sermorelin: Half-Life, Dosing, and GH Pulse Differences

CJC-1295 and Sermorelin are both GHRH analogs—they mimic the body's natural growth hormone-releasing hormone and work through the same receptor on pituitary cells. But there the similarity largely ends. Their half-lives differ by orders of magnitude, which completely changes the GH release pattern they produce, how you dose them, and what you're actually trying to achieve. Choosing between them (or choosing CJC-1295 with or without DAC) requires understanding these distinctions.

The GHRH analog family: where they sit

Natural GHRH (1-44) has a half-life of only a few minutes in circulation—rapidly degraded by dipeptidyl peptidase IV (DPP-IV) enzymes. Pharmaceutical development of GHRH analogs has focused on extending that half-life to make the peptide clinically practical.

Sermorelin (GHRH 1-29) is the first 29 amino acids of GHRH—the minimally active fragment that retains GHRH receptor binding. It extends the half-life modestly to about 10–20 minutes. Still short, but enough for a meaningful GH pulse when injected.

CJC-1295 without DAC (also called Mod GRF 1-29) takes the same 1-29 sequence and adds specific amino acid substitutions that resist DPP-IV degradation. Half-life: approximately 30 minutes to 2 hours. It produces a cleaner, more potent GH pulse with less frequent dosing than sermorelin.

CJC-1295 with DAC (Drug Affinity Complex) adds a lysine-reactive group that covalently binds to circulating albumin. This dramatically extends the half-life to 6–8 days—a completely different pharmacokinetic profile. A single injection maintains elevated GHRH signaling for nearly a week.

The DAC question: what it changes

The addition of DAC transforms CJC-1295 from a pulse-based peptide into a slow-release, blunting GH elevation. This is not just a dosing convenience issue—it fundamentally changes the biological effect.

Natural GH secretion is pulsatile. The pituitary releases GH in discrete pulses—primarily at night during deep sleep, with smaller pulses throughout the day. This pulsatile pattern matters: GH receptors downregulate with constant stimulation, and many of GH's beneficial effects (IGF-1 production, lipolysis, muscle protein synthesis) depend on these distinct pulses followed by return to baseline.

CJC-1295 with DAC creates a sustained, non-pulsatile GHRH signal. This produces a "GH bleed"—elevated baseline GH and IGF-1 without distinct pulses. Some research suggests this pattern is less optimal for body composition than pulsatile release, and there's theoretical concern about the effects of sustained non-pulsatile GH elevation on insulin resistance and other metabolic parameters.

CJC-1295 without DAC and Sermorelin both produce pulsatile GH release. The distinction is the pulse amplitude and duration:

| Parameter | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) | |---|---|---|---| | Half-life | ~10–20 min | ~30 min–2 hours | 6–8 days | | GH release pattern | Pulsatile | Pulsatile | Continuous ("bleed") | | Dosing frequency | Daily | Daily (or 2–3x/week) | 1–2x/week | | Peak GH amplitude | Moderate | High | Moderate sustained | | IGF-1 elevation | Moderate | Moderate-high | High | | DPP-IV resistance | Minimal | High | High | | Albumin binding | No | No | Yes |

Dosing protocols side by side

Sermorelin:

• Dose: 200–500 mcg per injection
• Frequency: Daily, typically before sleep
• Timing: Bedtime aligns with natural GH pulse
• Cycle: 3–6+ months ongoing

CJC-1295 without DAC (Mod GRF 1-29):

• Dose: 100–300 mcg per injection
• Frequency: Daily, or 5 days on/2 days off
• Timing: Bedtime, or paired with ipamorelin 2x/day
• Cycle: 3–6+ months ongoing

CJC-1295 with DAC:

• Dose: 1,000–2,000 mcg per injection
• Frequency: Once or twice per week
• Timing: Any time; sustained release eliminates timing concerns
• Cycle: 3–6 months; often done in 8–12 week cycles with breaks

Which produces better GH pulses?

For maintaining physiological GH pulsatility, CJC-1295 without DAC is generally preferred over CJC-1295 with DAC. It produces a clean, potent pulse while still returning to baseline between doses. Many anti-aging physicians use Mod GRF 1-29 (CJC-1295 no-DAC) paired with ipamorelin as the gold-standard combination specifically because it preserves pulsatility.

Sermorelin produces a similar pulsatile pattern but with lower amplitude GH peaks due to its shorter half-life and greater DPP-IV degradation. Some practitioners view this as more conservative and therefore safer, particularly for first-time users.

When CJC-1295 with DAC makes sense

Despite the pulsatility concerns, CJC-1295 with DAC has legitimate applications:

• When adherence to daily injection is a barrier (once-weekly dosing is a significant convenience advantage)
• For significant body composition goals where consistently elevated IGF-1 is the primary target
• In older adults where the pulsatile pattern may matter less relative to the goal of simply raising IGF-1 levels overall

The tradeoff is accepting a non-physiological GH pattern in exchange for convenience and higher sustained IGF-1.

Sermorelin's advantages

Despite CJC-1295 being pharmacologically superior in most respects, Sermorelin has real advantages:

1. Longest clinical track record: Sermorelin (as Geref) was the first FDA-approved GHRH analog and has decades of clinical data.
2. Prescribability: More physicians are comfortable prescribing sermorelin because of its established safety profile.
3. Self-limiting via feedback: Sermorelin is more governed by somatostatin feedback than the modified CJC-1295 analogs, potentially reducing risk of oversupplementation.
4. Cost: Typically the cheapest option among the GHRH analogs through compounding pharmacies.

For a more conservative entry into GH peptide therapy—particularly for older adults or first-time users—sermorelin remains a defensible choice. The CJC-1295 complete guide and sermorelin guide cover each in more depth.

The combination protocol

The most prescribed combination in anti-aging medicine today is Ipamorelin + CJC-1295 (no DAC). This pairs a GHRH analog (CJC-1295 no-DAC) with a GHRP (ipamorelin) to stimulate GH release through two different receptors simultaneously. When a GHRH signal and a GHRP signal arrive at the pituitary at the same time, the GH release is 3–10x greater than either alone. See the ipamorelin CJC-1295 stack guide for complete protocols.

The bottom line

Sermorelin is the safest, most conservative, most physiologically similar option—ideal for new users and physicians who want the most established safety data. CJC-1295 without DAC (Mod GRF 1-29) is an improved version of the same mechanism with better DPP-IV resistance, higher GH pulses, and the same pulsatile release pattern—it's generally preferred over sermorelin by practitioners who are comfortable with the newer peptides. CJC-1295 with DAC trades physiological pulsatility for once-weekly dosing convenience and sustained IGF-1 elevation—useful for adherence-limited users and those primarily targeting IGF-1.

---

Frequently Asked Questions

Q: Is "CJC-1295 without DAC" the same as "Mod GRF 1-29"? Yes. Modified GRF 1-29 (Mod GRF 1-29) and CJC-1295 without DAC refer to the same peptide—the GHRH 1-29 fragment with four amino acid substitutions for DPP-IV resistance. The naming is confusing because some vendors use these terms interchangeably. If a product is labeled "CJC-1295 no DAC" or "Mod GRF 1-29," it's the same compound.

Q: Why did CJC-1295 largely replace sermorelin in clinical practice? CJC-1295 (no DAC) is more resistant to DPP-IV degradation, produces higher-amplitude GH pulses at similar doses, and doesn't require the very precise bedtime timing that sermorelin's shorter half-life demands. It's essentially a better-engineered version of the same mechanism, which is why most anti-aging physicians who offer GH peptides have shifted to it.

Q: Is CJC-1295 with DAC safe for long-term use? The safety profile appears good in available data, but long-term human studies are limited. The main concern is whether sustained non-pulsatile GH elevation mimics the risks associated with acromegaly (excess GH)—though therapeutic doses are far below acromegaly levels. Most protocols include breaks (cycling 8–12 weeks on, 4 weeks off) as a precaution.

Q: How do I know if my CJC-1295 is the DAC or no-DAC version? The key difference is appearance and dosing: CJC-1295 with DAC typically comes in 2mg vials and is dosed at 1–2mg per injection once or twice weekly. CJC-1295 without DAC typically comes in 2mg vials but is dosed at 100–300 mcg per injection daily. If your protocol calls for daily dosing at low mcg amounts, you likely have no-DAC. Always verify with the supplier.

Q: Can I switch from sermorelin to CJC-1295 mid-cycle? There's no pharmacological reason you couldn't switch, but most practitioners treat them as interchangeable at the same receptor. Switching mid-cycle is primarily a practical matter—no washout period is required since both work through the GHRH receptor and you're not switching receptor targets.

---

Compare your peptide protocol options and track your results with Optimize.